Respiratorius AB (publ) (FRA:HF00)

Market Cap	1.75M -39.3%
Revenue (ttm)	2.74K
Net Income	-608.67K
EPS	-0.09
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.2040
Previous Close	0.1805
Day's Range	0.2040 - 0.2040
52-Week Range	0.0958 - 0.7480
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 4, 2026

About Respiratorius AB

Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company’s products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 0
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HF00

Financial Performance

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error